Roflumilast is a novel, orally active phosphodiesterase 4 inhibitor currently under review by FDA for the treatment of patients with moderate-to-severe COPD.
In early November 2009, FDA approved revisions to the drug label for exenatide (Byetta, Amylin Pharmaceuticals), an injectable glucagon-like peptide-1 agonist for the treatment of type 2 diabetes mellitus.
Heart failure (HF) guideline-recommended aldosterone antagonist therapy was received by less than one-third of eligible patients participating in a quality improvement registry who had been hospitalized for HF.
Dabigatran, a new oral direct thrombin inhibitor, given to patients with atrial fibrillation at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians. Register now (it's free and quick) or Find out more.
Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
